Natera, INC. (NTRA) — SEC Filings

Overview

Natera, INC. (NTRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: Natera, Inc. filed an 8-K on December 5, 2025, reporting unregistered sales of equity securities and other events. The filing details events that occurred on December 4, 2025, and includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices

Sentiment Summary

Across 36 filings, the sentiment breakdown is: 1 bullish, 31 neutral, 4 mixed. The dominant filing sentiment for Natera, INC. is neutral.

Filing Type Overview

Natera, INC. (NTRA) has filed 17 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 1 DEFA14A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (36)

• Natera, Inc. Files 8-K on Equity Sales and Other Events — 8-K · Dec 5, 2025 Risk: medium
  Natera, Inc. filed an 8-K on December 5, 2025, reporting unregistered sales of equity securities and other events. The filing details events that occurred on De
• Natera's Revenue Soars 34% But Losses Double on R&D, SG&A Spikes — 10-Q · Nov 7, 2025 Risk: high
  Natera, Inc. (NTRA) reported a significant increase in total revenues for the nine months ended September 30, 2025, reaching $1,640,615 thousand, up from $1,220
• Natera, Inc. Files 8-K on Financials — 8-K · Nov 6, 2025 Risk: low
  Natera, Inc. filed an 8-K on November 6, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The
• Natera's Revenue Jumps 11% as Losses Narrow in Q2 — 10-Q · Aug 8, 2025 Risk: medium
  Natera, Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $136.76 million, up from $122.85 million in the prior
• Natera, Inc. Files 8-K on Financials — 8-K · Aug 7, 2025 Risk: low
  Natera, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
• Natera, Inc. Files 8-K: Director/Officer Changes & Shareholder Votes — 8-K · Jun 18, 2025 Risk: medium
  Natera, Inc. filed an 8-K on June 18, 2025, reporting events as of June 12, 2025. The filing covers the departure of directors or certain officers, the election
• Natera's Q1 2025 10-Q: Assets vs. Liabilities — 10-Q · May 9, 2025 Risk: medium
  Natera, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $135.93 million and total liabilities of $132.65 million
• Natera, Inc. Files 8-K on Financials — 8-K · May 8, 2025 Risk: low
  Natera, Inc. filed an 8-K on May 8, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits,
• Natera Inc. DEF 14A: Executive Compensation Details — DEF 14A · Apr 24, 2025 Risk: medium
  Natera, Inc. filed a DEF 14A on April 24, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate gove
• Natera, Inc. Files 8-K: Officer/Director Changes & Compensation — 8-K · Mar 12, 2025 Risk: medium
  Natera, Inc. filed an 8-K on March 12, 2025, reporting events as of March 6, 2025. The filing primarily concerns the departure of directors or certain officers,
• Natera, Inc. Files 2024 Annual Report — 10-K · Feb 28, 2025 Risk: medium
  Natera, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting its financial performance and business operations. The company, incorporated
• Natera, Inc. Files 8-K on Financials — 8-K · Feb 27, 2025 Risk: low
  Natera, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exh
• Natera, Inc. Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  Natera, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing includes financ
• Natera Appoints New Director to Board — 8-K · Dec 6, 2024 Risk: low
  Natera, Inc. announced on December 2, 2024, a change in its board of directors. Specifically, Dr. Paul J. Hastings has been appointed as a new director, effecti
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Natera, Inc. Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
  Natera, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. Th
• Natera Q3 Revenue Rises to $124M, Operating Cash Burn Continues — 10-Q · Nov 12, 2024 Risk: medium
  Natera, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $1.238 billion and total liabilities of $115.171 mill
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Oct 22, 2024
• Natera, Inc. Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Natera, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter of 2024
• Natera, Inc. Files 8-K with Financial Updates — 8-K · Aug 8, 2024 Risk: low
  On August 8, 2024, Natera, Inc. filed an 8-K report detailing its financial results and other material information. The filing includes information related to i
• Natera Acquires Invitae's Genetic Testing Assets — 8-K · Jul 22, 2024 Risk: medium
  Natera, Inc. announced on July 19, 2024, that it has entered into a definitive agreement to acquire the assets of Invitae Corporation's genetic testing business
• Natera, Inc. Files 8-K: Director Changes & Officer Appointments — 8-K · Jun 18, 2024 Risk: low
  Natera, Inc. filed an 8-K on June 18, 2024, reporting events that occurred on June 12, 2024. The filing primarily concerns the departure of a director, the elec
• SC 13G/A Filing — SC 13G/A · Jun 7, 2024
• Natera Inc. Files Proxy Statement Supplement — DEFA14A · Jun 5, 2024 Risk: low
  Natera, Inc. filed a Definitive Proxy Statement (DEFA14A) on June 5, 2024, supplementing its proxy materials for the Annual Meeting of Stockholders scheduled fo
• Natera, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: medium
  Natera, Inc. (NTRA) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Natera, Inc. reported financial results for the quarter ended March 31, 2024.
• Natera, Inc. Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
  On May 9, 2024, Natera, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing indicates the company's principal execu
• Natera, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 24, 2024 Risk: low
  Natera, Inc. (NTRA) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Natera, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 24, 202
• Natera, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  Natera, Inc. (NTRA) filed a Annual Report (10-K) with the SEC on February 29, 2024. Natera, Inc. reported its 2023 fiscal year-end results on December 31, 2023.
• Natera Files 8-K on Financial Condition and Operations — 8-K · Feb 28, 2024 Risk: low
  Natera, Inc. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing indicates that the report was made pu
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BlackRock Discloses 7.3% Stake in Natera Inc. — SC 13G · Jan 31, 2024
  BlackRock Inc., a major investment firm, reported on January 31, 2024, that it holds a significant stake in Natera, Inc. (NTRA) as of December 31, 2023. This fi
• JPMorgan Cuts Natera Stake to 4.0% as of Dec 29 — SC 13G/A · Jan 23, 2024
  JPMorgan Chase & Co. filed an amended Schedule 13G/A on January 23, 2024, indicating a change in their beneficial ownership of Natera, Inc. common stock as of D
• Natera Files 8-K for Jan 17 Event; Routine Compliance Update — 8-K · Jan 22, 2024
  Natera, Inc. filed an 8-K on January 22, 2024, reporting an event that occurred on January 17, 2024. This filing is a routine 'Other Events' disclosure, indicat
• Natera Files 8-K for Financial Results & Exhibits Disclosure — 8-K · Jan 9, 2024
  Natera, Inc. filed an 8-K on January 9, 2024, indicating that it will be disclosing its "Results of Operations and Financial Condition" and "Financial Statement

Risk Profile

Risk Assessment: Of NTRA's 26 recent filings, 1 were flagged as high-risk, 12 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Natera, INC.'s most recent 10-Q filing (Nov 7, 2025):

• Revenue: $1,640,615
• Net Income: -$255,418
• EPS: -$0.64
• Debt-to-Equity: 0.46
• Cash Position: $1,041,438
• Operating Margin: -17.5%
• Total Assets: $1,821,482
• Total Debt: $569,294

Key Executives

• Austin, Texas
• San Carlos, California
• Dr. Paul J. Hastings
• Steve Chapman

Industry Context

Natera operates in the rapidly evolving molecular diagnostics and genetic testing market, characterized by significant technological advancements and increasing demand for personalized medicine. Key segments include women's health (prenatal screening), oncology (cancer detection and monitoring), and organ health. The competitive landscape features both established players and innovative startups, with a strong emphasis on clinical utility, reimbursement, and regulatory approval.

Top Tags

financial-reporting (6) · 8-K (4) · financial-condition (4) · financials (4) · operations (3) · results-of-operations (3) · filing (3) · 10-Q (3) · sec-filing (3) · Natera (3)

Key Numbers

• Total Revenues (9 months ended Sep 30, 2025): $1,640,615 — Increased 34.4% from $1,220,850 thousand in 2024
• Net Loss (9 months ended Sep 30, 2025): $255,418 — Widened from $136,655 thousand in 2024
• Research and Development Expenses (9 months ended Sep 30, 2025): $448,917 — Increased 63.4% from $274,677 thousand in 2024
• Selling, General and Administrative Expenses (9 months ended Sep 30, 2025): $885,962 — Increased 46.1% from $606,397 thousand in 2024
• Cash, Cash Equivalents and Restricted Cash (Sep 30, 2025): $1,041,438 — Increased from $945,587 thousand at Dec 31, 2024
• Shares Issued and Outstanding (Sep 30, 2025): 137,533 — Increased from 132,646 shares at Dec 31, 2024
• Cash Provided by Operating Activities (9 months ended Sep 30, 2025): $141,413 — Increased from $82,777 thousand in 2024
• Net Loss Per Share (3 months ended Sep 30, 2025): $0.64 — Increased from $0.26 in 2024
• Revenue for Q2 2025: $136.76M — Increased from $122.85M in Q2 2024, an 11.3% rise.
• Net loss per share for Q2 2025: $0.74 — Improved from $0.86 in Q2 2024.
• Revenue for six months ended June 30, 2025: $269.43M — Increased from $238.48M in the same period of 2024.
• Net loss per share for six months ended June 30, 2025: $1.24 — Improved from $1.69 in the same period of 2024.
• Accumulated deficit as of June 30, 2025: $2.34B — Indicates historical losses.
• Research and development expenses for six months ended June 30, 2025: $79.6M — Significant ongoing investment.
• Total Assets: $135.93M — As of March 31, 2025

Related Companies

ILMN · EXAS · GH · NVTA

Frequently Asked Questions